Are you a healthcare professional?

This website contains promotional information for Chiesi's respiratory products, and is intended solely for UK healthcare professionals. Please confirm below, or go back to the home page.

UK-RES-2101606 August 2021

You are now leaving Chiesi's website

By clicking this link, you will be taken to a website that is not owned or controlled by Chiesi. Chiesi is not responsible for the content provided on that site.

Go back

UK-RES-2101574 August 2021


Think triple (ICS/LABA/LAMA),
think Trimbow®

The only extrafine formulation ICS/LABA/LAMA combination1-3

Designed to reach the large and small airways1,2,4

The only ICS/LABA/LAMA combination available in both a pMDI and NEXThaler (DPI) for the maintenance treatment of adult patients with moderate to severe COPD who require triple therapy1–3

Trimbow pMDI 87/5/9 and NEXThaler 88/5/9 are indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1 of the SPC).1,2

Trimbow® Device

Each dose contains three molecules:1,2

  • Beclometasone
  • Formoterol
  • Glycopyrronium
Trimbow is a maintenance treatment for your adult patients with moderate to severe COPD not adequately treated with ICS/LABA or LABA/LAMA who require triple therapy1,2

Extrafine formulation like Fostair® (beclometasone/formoterol)1,2,5,6

Choice of pMDI or NEXThaler device to meet your patients’ needs1,2

Trimbow pMDI 87/5/9 demonstrated reduction in moderate to severe exacerbations vs.:1

  • LAMA (Spiriva® HandiHaler®)7
  • ICS/LABA (Fostair pMDI 100/6) – secondary endpoint8
  • LABA/LAMA (Ultibro® Breezhaler®)9

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.